Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The impact of post-discharge bleeding (PDB) on the major cardiovascular events (MACEs) in dual antiplatelet therapy (DAPT) treated Chinese acute coronary syndrome (ACS) patients underwent percutaneous coronary intervention (PCI)

Trial Profile

The impact of post-discharge bleeding (PDB) on the major cardiovascular events (MACEs) in dual antiplatelet therapy (DAPT) treated Chinese acute coronary syndrome (ACS) patients underwent percutaneous coronary intervention (PCI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2018

At a glance

  • Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2018 New trial record
    • 12 Mar 2018 Results presented at the 67th Annual Scientific Session of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top